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ABSTRACT 
Background    
Evaluation of health-related quality of life is (HRQL) important in improving the quality of patient 
care. The aim of this study was to determine the psychometric properties of the HeartQoL in 
patients with ischemic heart disease (IHD), specifically angina, myocardial infarction (MI), or 
ischemic heart failure. 
Methods 
Data for the validation of the HeartQoL questionnaire were collected in 1) a cross-sectional survey 
and 2) a prospective substudy of patients undergoing either a percutaneous coronary intervention 
(PCI) or referred to cardiac rehabilitation (CR) were analyzed to determine the reliability, validity, 
and responsiveness of the HeartQoL questionnaire. 
Results 
We enrolled 6,380 patients (angina, n=2,110, 33.1%; MI, n=2,350, 36.8%; HF, n=1,920, 30.1%) 
across 22 countries speaking 15 languages.  The HeartQoL questionnaire comprises 14-items with 
physical and emotional subscales and a global score (range 0 to 3 (poor to better HRQL).  
Cronbach’s alpha consistently was ≥0.80; convergent validity correlations between similar 
HeartQoL and SF-36 subscales were significant (r≥ 0.60, p<0.001); discriminative validity was 
confirmed with predictor variables - health transition, anxiety, depression, and functional status.  
HeartQoL score changes following either PCI or CR were significant (p<0.001) with effect sizes 
from 0.37 to 0.64. 
Conclusion 
The HeartQoL questionnaire is reliable, valid, and responsive to change allowing clinicians and 
researchers to a) assess baseline HRQL, b) make between-diagnosis comparisons of HRQL, and 
c) evaluate change in HRQL in patients with angina, myocardial infarction, or heart failure with a 
single IHD-specific HRQL instrument.  
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INTRODUCTION 
 Ischaemic heart disease (IHD) accounts for approximately 15% of all deaths in Europe 1 
and 16% in the USA 2.  With a wide range of health status deficits, treatment and therapeutic goals 
for patients with IHD include reduced mortality and an enhanced quality of the longer life.  The 
Institute of Medicine has emphasized patient-centered care as one means to improve the quality of 
health care for patients 3.  Both the US Food and Drug Administration 4 and the European 
Medicines Agency 5 have provided guidance for selecting and using patient-reported outcome 
instruments.  Further, the National Heart, Lung and Blood Institute has stressed the importance of 
patient-reported health status measures such as health-related quality of life (HRQL) in clinical care 
and relevant clinical trials for patients with IHD 6.   
 Patients with IHD present on a continuum of disease with angina, myocardial infarction (MI), 
and ischemic heart failure, the three most commonly reported IHD diagnoses.  Between-diagnosis 
HRQL comparisons require the use of either generic HRQL questionnaires or disease-specific 
questionnaires which need validation in each of the diagnoses within a specific disease.  Validated 
core disease-specific HRQL questionnaires have been available for about 20 years 7, 8 in oncology but 
not in cardiology.  When the HeartQoL Project was initiated 9; generic, rather than specific, HRQL tools 
were used 10, and continue to be used 11, for making between-diagnosis HRQL comparisons in 
patients with IHD.  The HeartQoL Project was designed to develop a single reliable and valid core IHD-
specific, HRQL questionnaire, to be called the HeartQoL, for comparing HRQL outcomes in patients 
with angina pectoris, MI, or ischemic heart failure with left ventricular systolic dysfunction 9.   
 With the trend toward globalization in health care, HRQL instruments need to be shown to be 
reliable and valid in an international setting.  The development of the HeartQoL, which consists of 14-
items with a 10-item physical and a 4-item emotional subscale scored from 0 (poor HRQL) to 3 (better 
HRQL) with a global score if needed, was based on data provided by an international cohort of 6,384 
patients with angina, MI, or heart failure and is described elsewhere 12.  The purpose of this report is to 
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report on the psychometric properties of the HeartQoL.  
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METHODS 
 Per design, the international HeartQoL Project was conducted between 2002 and 2011 in 
22 countries and 15 languages in two phases 9: 1) a cross-sectional survey phase to develop the 
HeartQoL questionnaire 12 and determine it’s reliability and validity; and 2) a prospective 
responsiveness phase with two study arms, percutaneous coronary intervention (PCI) and cardiac 
rehabilitation (CR), to determine it’s responsiveness. 
 
Patients 
 The HeartQoL Project target was to enroll at least 1) 315 patients (105 with angina, 105 with 
MI and 105 with heart failure) in an international cross-sectional study and 2) 150 patients with IHD in 
each of the two arms in the prospective study 9.  The eligibility criteria are detailed elsewhere 12 and 
include patients with documented angina (Canadian Cardiovascular Society (CCS) functional status 
classification Class II, II, or IV) 13, MI, or ischemic heart failure (New York Heart Association (NYHA) 
functional status classification Class II, III, and IV) 14, ≥18 years old, and considered by the referring 
physician 1) to be able to complete the self-administered battery of HRQL instruments, 2) not have 
serious psychiatric disorder, and 3) not be a current substance abuser. 
 
Questionnaires 
 All patients in the cross-sectional survey completed a sociodemographic questionnaire, the 
Short-Form 36 (SF-36) 15, the Hospital Anxiety and Depression Scale (HADS) 16, and three IHD-
specific questionnaires, the Seattle Angina Questionnaire (SAQ) 17, the MacNew Heart Disease 
Health-related Quality of Life Questionnaire (MacNew) 18, and the Minnesota Living With Heart Failure 
(MLHF) Questionnaire 19.  Face and content validity of the HeartQoL items are assumed as the 
psychometric properties of the three specific IHD questionnaires have been demonstrated.  All patients 
undergoing PCI or referred to CR completed the HeartQoL, a sociodemographic questionnaire, the SF-
 8
36, and the HADS at baseline and the HeartQoL, the SF-36, and the HADS 10-12 weeks after PCI and 
at the end of CR. 
 
Psychometric properties  
 The following psychometric properties of the HeartQoL were assessed using 
recommended criteria 20. 
Reliability 
 Internal consistency reliability (Cronbach’s a) was assessed (r≥0.70 considered acceptable 
for group and ≥0.90 for individual comparisons) 21.   
Validity 
 a. Convergent validity 
 Hypothesizing, a priori, strong correlations between similar SF-36 and HeartQoL constructs 
(r≥0.50 21) and lower correlations between dissimilar constructs, convergent validity of the 
HeartQoL was tested.  The correlation coefficients between similar and dissimilar scales were 
tested for significant differences 22.   
 b. Discriminative validity 
 The “known-groups” test for expected relationships 23 was used to determine discriminative 
validity.  Groups were defined as follows: HADS scores for anxiety and depressive symptoms 
(score ≤7= absent, >7= present); SF-36 health transition (deteriorated, no change, improved 
health); CCS and NYHA functional class (II, III/IV). 
 c. Evaluative validity 
 Paired t-tests were used to test for HeartQoL score changes.  Responsiveness was 
reported as effect size (ES; small: ≥0.20, <0.50; moderate: 0.50, <0.80; and large: ≥0.80) using the 
standardized response mean [SRM] methodology (ES = A – B) / D) where A= time 2 mean, B= 
time 1 mean, and D= score change standard deviation 24.
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RESULTS 
 
Patients (Table 1) 
 A cohort of 6,384 patients, living in 5 different geographical regions with 54 sites in 22 
countries (15 languages), was enrolled in the HeartQoL Project 12.  Patients with angina (n=2,110; 
33.1%), MI (n=2,350; 36.8%), or heart failure (n=1,920; 30.1%) were referred.  Women made up 
25% (n=1,694) of the cohort whose mean age was 62.5 years (SD= 11.3).  Specific clinical and 
sociodemographic details are provided elsewhere 12. 
 In the responsiveness substudy, 398 patients undergoing PCI in 10 countries speaking 
(eight languages) were enrolled (Danish, English [Ireland, USA], Flemish, French, German [Austria, 
Switzerland], Norwegian, Portuguese, and Spanish).  In the CR arm, 383 patients from eight 
countries (six languages) were enrolled (Danish, English [Ireland, USA], Flemish, French, German 
[Austria, Switzerland], and Spanish).   
HeartQoL scores (Table 1)  
 The mean baseline HeartQoL global score in the group as a whole was 2.2±0.5.  Global 
and physical subscale scores (better HRQL) were highest in patients with MI, intermediate with 
angina, and lowest with heart failure (p<0.001).  Emotional subscale scores were highest in 
patients with MI and lower, but similar, in patients with angina and heart failure.  Individual patient 
HeartQoL scores ranged from 0.0 to 3.0.  Less than 1.0 % of the patients scored at the floor on any 
of the HeartQoL scales.  Fewer than 9% of the patients scored at the ceiling on the HeartQoL 
global score, ≤14 % on the physical subscale, and ≤27 % on the emotional subscale.  
Internal consistency reliability (Table 1) 
 Cronbach’s α for the global score and each subscale was always between 0.80 and 0.91. 
Convergent validity (Table2) 
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 The correlations between similar HeartQoL and SF-36 subscales were ≥0.60 and always 
significant.  As hypothesized, all correlations between dissimilar HeartQoL and SF-36 scales were 
lower (all r≤0.38, p<0.001).  
Discriminative validity (Table 3) 
 Discriminative validity of the HeartQoL was confirmed in the group as a whole and each 
diagnosis.  HeartQoL scores were always higher [better HRQL] in patients with 1) ‘no change’ or 
‘improved’ vs. ‘deteriorated’ health status 2) ‘without’ vs. ‘with’ anxiety or depression, and 3) 
functional class ‘II’ vs. ‘III/IV’ in patients with angina or heart failure (p<0.001). 
Responsiveness (Table 4) 
 The HeartQoL global, physical, and emotional subscale score changes improved with both 
interventions (p<0.001).  The ES was 0.51 for the global, 0.49 for the physical, and 0.37 for the 
emotional subscale scores with PCI and 0.64, 0.59, and 0.47, respectively, with CR.  The ES for 
the HeartQoL and SF-36 physical and emotional subscales were similar. 
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DISCUSSION 
 The HeartQoL questionnaire is a reliable and valid 14-item IHD-specific core HRQL 
questionnaire for patients with angina, MI, or ischemic heart failure.  The HeartQoL questionnaire 
was developed and validated in a cohort of 6,384 patients with IHD who live in 22 countries and 
speak one of 15 languages; an independent cohort of 781 patients either undergoing PCI (n= 398) 
or referred to CR (n=383) from 10 countries speaking one of eight languages provided 
responsiveness data.  Performing well on key psychometric attributes for HRQL instruments 20, the 
HeartQoL has potential as a core IHD-specific HRQL questionnaire and demonstrated that patients 
with MI have better HRQL than patients with angina who in turn have better HRQL than patients 
with heart failure.  
 The 14-items in the HeartQoL scale cluster as a 10-item physical and a 4-item emotional 
subscale providing both assessment and evaluation of how a patient with angina, MI, or heart 
failure perceives that he/she is bothered by their heart disease.  Guidelines for key attributes of 
HRQL instruments include the conceptual and measurement model, reliability, validity, 
responsiveness, and respondent and administrative burden 20.  We assumed, a priori, face and 
content validity of the candidate item pool for the HeartQoL as the original three HRQL 
questionnaires had previously been validated in patients with angina (SAQ), MI (MacNew), or heart 
failure (MLHF).   
 Internal consistency reliability, i.e., freedom from random error, exceeded the 
recommended criterion for group HRQL comparisons with Cronbach’s α > 0.70 20 on each 
HeartQoL scale in the total group and each diagnostic group.  Examination of test-retest 
reproducibility was not possible as the HeartQoL questionnaire was developed in a cross-sectional 
survey study. 
 Using the “known groups” approach 23, discriminative validity of the HeartQoL was 
confirmed with a) SF-36 health transition, b) HADS anxiety and depression, and c) CCS and NYHA 
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functional status.  Patients reporting their health as either “improved” or “no change” had 
significantly higher or better HRQL when compared to patients who reported “deteriorated” health.  
Patients without anxiety or depression had significantly higher HeartQoL scores than patients who 
were anxious or depressed.  The same pattern applied to functional class with higher HRQL scores 
in patients with angina CCS or heart failure NYHA class II compared to class III/IV.  The overall 
pattern with the HeartQoL is that patients with MI have a better HRQL than patients with angina 
who, in turn, have a better HRQL than patients with heart failure.  This HRQL pattern is consistent 
with observations using generic HRQL instruments, specifically the SF-36 15 and the EuroQoL EQ-
5D 25, and with the MacNew, a core IHD-specific HRQL instrument which has been validated in 
patients with angina, MI, and heart failure since initiation of the HeartQoL Project 26-28.   
 Pre-post PCI and CR HeartQoL score changes were significant (p< 0.001).  While the t-
test estimates the significance of observed pre-post-intervention changes, the effect size 
additionally provides a standardized measure of the magnitude of an effect to identify whether the 
observed differences matter, something that is important to clinicians.  With PCI, the ES for the 
HeartQoL global score and each subscale ES was ‘weak’.  On the other hand, the ES for the global 
score and physical subscale was ‘moderate’ with CR.  The standard deviations in the physical and 
emotional subscale HeartQoL scores after PCI (0.8 to 0.9) suggest that a considerable number of 
patients in this study were still symptomatic 12 weeks after PCI.  Patients undergoing PCI in our 
substudy were similar to the relatively low-risk patients in the COURAGE trial HRQL substudy 
where 47% of the patients were not angina-free three months after PCI 29.  This may, at least 
partially, be responsible for the smaller HeartQoL ES observed with PCI than CR in this study.  
While PCI is a procedure aimed at the alleviation of a single symptom, CR, on the other hand, 
entails "coordinated, multifaceted interventions designed to optimize a cardiac patient’s physical, 
psychological, and social functioning, in addition to stabilizing, slowing, or even reversing the 
progression of the underlying atherosclerotic processes, thereby reducing morbidity and mortality” 
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30
.  For these reasons, it should not be too surprising that the short-term impact of CR on HRQL is 
proportionately greater than with PCI which is consistent with the larger ES seen with CR in this 
study.  
 A “floor effect” occurs at the lowest possible score on an instrument indicating patients 
already have the lowest HRQL measurable and, conversely, a “ceiling effect” is the best HRQL 
measurable.  With <1% of the patients at the floor in the HeartQoL and with <14% and <9% on the 
physical subscale and global scores at the ceiling, the questionnaire appears to be sensitive to 
positive and negative changes in HRQL.  On the other hand, as 25% of the patients reported 
emotional subscale scores at the ceiling, assessing improvement in emotional HRQL may be 
somewhat more problematic.  This potentially would be of concern in a trial where the instrument 
was being used to assess change, as no further increase in HRQL would be possible for 25% of 
the patients.  However, the numbers of participants demonstrating “ceiling” effects in the present 
study is of less concern than might appear at first sight.  All HRQL instruments applied to “routine 
care” patients are likely to have significant proportions scoring at or near the score indicating high 
HRQL.  However, in any intervention trial in which HRQL is an endpoint, it is unlikely that the 
inclusion criteria will result in the inclusion of a substantial group where HRQL is already optimal, 
i.e., mean HeartQoL scores will be relatively low.   
 While respondent and administrative burden of the 14-item HeartQoL are low, the 
HeartQoL, as with any new HRQL instrument, will need continued extensive and rigorous 
examination of its psychometric properties before it can be considered as a standard for assessing 
and evaluating HRQL in patients with angina, MI, or heart failure.  The HeartQoL will need to be 
validated other languages and will need head-to-head comparisons with the other available core 
IHD-specific HRQL instrument, the MacNew 26-28.  Further HeartQoL research needs include the 
establishment of test-retest reliability; further examination of floor and ceiling effects and 
establishment of responsiveness in patients who speak other languages; interpretability including 
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identification of the minimal clinical improvement of the instrument; and examination of the effect of 
low literacy, common among patients 31 but not frequently assessed with IHD-specific HRQL 
instruments 32.   
 
CONCLUSIONS 
 The HeartQoL questionnaire, a new 14-item international core IHD-specific assessment 
and evaluation system on patient-reported HRQL is reliable, valid, and responsive in patients with a 
wide spectrum of IHD diagnoses, specifically angina, MI, and ischemic heart failure with the 
potential to have an impact on the quality of patient care.  The HeartQoL questionnaire with two 
subscales and a global score will allow clinicians and researchers to a) assess baseline HRQL, b) 
make between-diagnosis comparisons of HRQL, and c) evaluate change in HRQL in patients with 
angina, MI, and heart failure undergoing interventions designed to improve patient HRQL and 
reduce the cardiovascular burden on patients and their families who live with heart disease.  
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Table 1. Patient characteristics and HeartQoL questionnaire mean (± standard 
deviation) scores; ceiling (high HRQL) and floor (poor HRQL) effects; and internal 
consistency with Cronbach’s a in the total group and in patients with angina, myocardial 
infarction (MI), or heart failure 
 
 
 
 
Total Group 
(n=6,384) 
Angina 
(n=2,111) 
MI 
(n=2,351) 
Heart 
failure 
(n=1,922) 
p-value *  
Patient 
characteristics 
     
Age (years 62.5 (11.3) 63.1 (10.2) 59.7 (11.4) 65.1 (11.5) <0.001a,b,c 
Gender (male) 
 
75.2% 72.4% 75.9% 77.2% <0.001a,c 
HeartQoL: 
     
Physical score 2.2 (0.7) 2.2 (0.6) 2.4 (0.6) 2.0 (0.7) <0.001 a,b,c 
Ceiling effect 8.1% 6.2% 13.4% 3.8%  
Floor effect 0.2% 0.1% 0.1% 0.4%  
Cronbach’s a 
 
0.90 0.89 0.90 0.90  
Emotional score 2.4 (0.6) 2.3 (0.6) 2.4 (0.6) 2.3 (0.7) =0.003 a,b 
Ceiling effect 25.2% 23.9% 26.3 25.4 %  
Floor effect 0.6% 0.6% 0.4% 0.9%  
Cronbach’s a 
 
0.81 0.80 0.81 0.82  
Global score 2.2 (0.5) 2.2 (0.6) 2.4 (0.5) 2.1 (0.6) <0.001 a,b,c 
Ceiling effect 5.2% 4.0% 8.3% 2.8%  
Floor effect 0.1% 0.1% 0.0% 0.1%  
Cronbach’s a 
 
0.91 0.90 0.90 0.91  
 
p-value between diagnosis with ANOVA (post-hoc Bonferroni correction; in case of inhomogeneous 
variances, Welch’s F-statistic and post-hoc Games Howell correction) and with Chi-square for 
proportions 
 
a, AP vs. MI; b, MI vs. HF; c, AP vs. HF 
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Table 2. Convergent validity of the HeartQoL physical and emotional subscales with 
the Short Form-36 physical (SF-36 PCS} and the Short Form-36 mental component scale 
(SF-36 MCS) in the total group of patients with IHD and in patients with angina, myocardial 
infarction (MI), or heart failure  
 
IHD SF-36 PCS (r) SF-36 MCS 
(r) 
p-value* 
HeartQoL Physical 0.68** 0.36** <0.001 
HeartQoL Emotional 0.28** 0.60** <0.001 
p-value# <0.001 
 
<0.001  
ANGINA 
   
HeartQoL Physical 0.64** 0.38** <0.001 
HeartQoL Emotional 0.28** 0.65** <0.001 
p-value# <0.001 
 
<0.001  
MI 
   
HeartQoL Physical 0.64** 0.37** <0.001 
HeartQoL Emotional 0.25** 0.62** <0.001 
p-value# <0.001 
 
<0.001  
HEART FAILURE 
   
HeartQoL Physical 0.67** 0.34** <0.001 
HeartQoL Emotional 0.31** 0.60** <0.001 
p-value# <0.001 <0.001  
 
 # Steiger’s test for comparing Pearson correlation coefficients 
 **  p-value for correlation coefficients always < 0.001 
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Table 3. Discriminative validity of the HeartQoL global scale and physical and 
emotional subscales using 1) SF-36 health transition, anxiety and depression (Hospital 
Anxiety and Depression Scale) in the total group and in patients with angina, myocardial 
infarction, or heart failure, 2) functional status with Canadian Cardiovascular Society (CCS) 
in patients with angina, and 3) New York Heart Association classification (NYHA) in patients 
with heart failure   
 
Total group HeartQoL 
Global 
HeartQoL 
Physical 
HeartQoL 
Emotional 
SF-36 health transition 
Improve (n= 1572) 
No change (n=1821) 
Deteriorate (n= 2653) 
p-value #  
 
 
2.4 (0.5) 
2.4 (0.5) 
2.0 (0.6) 
<0.001 a,b 
 
2.4 (0.6) 
2.3 (0.6) 
2.0 (0.7) 
<0.001 a,b 
 
2.5 (0.6) 
2.5 (0.6) 
2.2 (0.7) 
<0.001 a,b 
Anxiety (HADS) 
No (n=3973) 
Yes (n=2042) 
 
 
2.4 (0.5) 
1.9 (0.6) * 
 
 
2.3 (0.6) 
2.0 (0.7) * 
 
 
2.6 (0.5) 
1.9 (0.7) * 
 
Depression (HADS) 
No (n=4500) 
Yes (n=1510) 
 
 
2.4 (0.5) 
1.8 (0.6) * 
 
 
2.3 (0.6) 
1.8 (0.7) * 
 
 
2.5 (0.5) 
1.9 (0.7) * 
 
Angina 
   
SF-36 health transition 
Improve (n= 513) 
No change (n=635) 
Deteriorate (n= 835) 
p-value #  
 
 
2.4 (0.5) 
2.3 (0.5) 
2.0 (0.6) 
<.001 a,b 
 
2.3 (0.6) 
2.3 (0.6) 
1.9 (0.6) 
<.001 a,b 
 
2.5 (0.6) 
2.4 (0.6) 
2.2 (0.7) 
<.001 a,b 
Anxiety (HADS) 
No (n=1225) 
Yes (n=747) 
 
 
2.4 (0.5) 
1.9 (0.6) * 
 
2.3 (0.5) 
1.9 (0.7) * 
 
2.6 (0.5) 
2.0 (0.6) * 
Depression (HADS) 
No (n=1,462) 
Yes (n=508) 
 
 
2.3 (0.5) 
1.9 (0.6) * 
 
2.3 (0.6) 
1.8 (0.7) * 
 
2.5 (0.5) 
1.9 (0.7) * 
CCS functional status 
II (n=1,299) 
III/IV (n=584) 
 
 
2.3 (0.5) 
2.1 (0.6) * 
 
2.2 (0.6) 
2.0 (0.7) * 
 
2.4 (0.6) 
2.3 (0.6) * 
Myocardial infarction 
   
SF-36 health transition 
Improve (n= 551) 
No change (n=590) 
 
2.5 (0.5) 
2.6 (0.4) 
 
2.6 (0.5) 
2.6 (0.5) 
 
2.5 (0.6) 
2.5 (0.5) 
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Deteriorate (n= 1072) 
p-value #  
 
2.2 (0.6) 
<.001 a,b 
2.2 (0.6) 
<.001 a,b 
2.3 (0.5) 
<.001 a,b 
Anxiety (HADS) 
No (n=1546) 
Yes (n=65) 
 
 
2.5 (0.4) 
2.1 (0.6) * 
 
2.5 (0.5) 
2.1 (0.7) * 
 
2.6 (0.5) 
1.9 (0.7)  
Depression (HADS) 
No (n=1783) 
Yes (n=415) 
 
 
2.5 (0.4) 
1.9 (0.6) * 
 
2.5 (0.5) 
2.0 (0.7) * 
 
2.5 (0.5) 
1.9 (0.7) * 
Heart failure 
   
SF-36 health transition 
Improve (n= 508) 
No change (n=596) 
Deteriorate (n= 746) 
p-value #  
 
 
2.3 (0.6) 
2.2 (0.6) 
1.8 (0.6) 
<.001 a,b 
 
2.2 (0.7) 
2.1 (0.7) 
1.7 (0.7) 
<.001 a,b 
 
2.5 (0.6) 
2.4 (0.6) 
2.2 (0.7) 
<.001 a,b 
Anxiety (HADS) 
No (n=1202) 
Yes (n=641) 
 
 
2.2 (0.6) 
1.8 (0.7) * 
 
2.1 (0.7) 
1.7 (0.7) * 
 
2.6 (0.5) 
1.9 (0.7) * 
Depression (HADS) 
No (n=1255) 
Yes (n=587) 
 
 
2.3 (0.5) 
1.7 (0.6) * 
 
2.1 (0.6) 
1.6 (0.7) * 
 
2.5 (0.5) 
1.9 (0.7) * 
NYHA functional status 
II (n= 1,024) 
III & IV (n=744) 
 
 
2.2 (0.6) 
1.9 (0.7) * 
 
2.1 (0.6) 
1.7 (0.7) * 
 
2.4 (0.6) 
2.2 (0.7 ) * 
 
# p-value between-diagnosis with ANOVA (post-hoc Bonferroni correction; with non-homogeneous 
variances, Welch’s F-statistic and post-hoc Games Howell correction) 
a: improve vs. deteriorate. b: no change vs. deteriorate 
*   p-value <0.001 
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Table 4  HeartQoL global and subscale p-values and effect sizes using the 
standardized response mean (SRM) for percutaneous coronary intervention [PCI] and 
cardiac rehabilitation [CR] in patients with ischemic heart disease  
 
 PCI [n=398] CR [n= 383] 
HeartQoL 
  
Physical subscale 
  
Baseline 1.6 [0.8] 2.0 [0.7] 
Follow- up 2.0 [0.8] 2.3 [0.6] 
p-value for change <0.001 <0.001 
effect size (SRM) 0.49 0.59 
 
  
Emotional subscale 
  
Baseline 1.9 [0.9] 2.2 [0.7] 
Follow- up 2.2 [0.8] 2.5[0.6] 
p-value for change <0.001 <0.001 
effect size (SRM) 0.37 0.47 
 
  
Global scale 
  
Baseline 1.7 [0.8] 2.0 [0.6] 
Follow- up 2.0 [0.7] 2.4 [0.5] 
p-value <0.001 <0.001 
effect size (SRM) 0.51 0.64 
 
  
 PCI [n=339] CR [n= 345] 
SF-36 
  
PCS 
  
Baseline 38.8 [9.9] 42.4 [9.3] 
Follow- up 43.0 [10.3] 46.5 [9.3] 
p-value for change <0.001 <0.001 
effect size (SRM) 0.46 0.54 
 
  
MCS 
  
Baseline 46.5 [11.6] 48.1 [11.1] 
Follow- up 49.6 [10.6] 51.8 [9.4] 
p-value for change <0.001 <0.001 
effect size (SRM) 0.30 0.45 
 
  
 
 
